While IO-108, an antibody targeting LILRB2, is in Phase 1 clinical development for solid tumors[135]; LILRB4 antibody (IO-202) is in phase 1 cohort expansion clinical trial [NCT0437243] in combination with azacitidine and venetoclax, for the treatment of AML and likely to be effective in monocytic AML[136,137]. Here, LILRB2 is linked to acute myeloid leukemia.